UPDATE 2-Roche dives deeper into gene therapy with $1.15 bln Sarepta licensing deal
December 23, 2019 at 08:33 AM EST
Roche Holding AG made its second major gene therapy deal in a year on Monday, spending $1.15 billion to obtain the rights to Sarepta Therapeutics Inc's investigational drug to treat duchenne muscular dystrophy (DMD) outside the United States.